Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06798623

Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells

This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Anterior Cruciate Ligament Reconstruction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Houston Methodist Hospital

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Madison Bowden

CONTACT

[email protected]

713-363-7390

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 years of age or older who are scheduled to undergo anterior cruciate ligament (ACL) reconstruction with bone-to-bone (BTB) patellar tendon autograft with the Principal Investigator (PI).
  • Receiving post-surgery physical therapy at a Houston Methodist physical therapy (PT) clinic.

Exclusion criteria

  • Under 18 years of age
  • Prior surgery on affected knee
  • Diabetes
  • Root repair, inflammatory arthropathy, or any other concomitant procedure that cannot follow an accelerated PT protocol or any concomitant procedure that the PI deems exclusionary
  • Unable to attend physical therapy at Houston Methodist
  • Vulnerable populations
  • Immunocompromised patients such as those being treated for cancer, kidney failure, etc.
  • Heart disease (including systolic blood pressure >180 mm Hg or heart failure)
  • Active infections
  • Non-English-speaking patients
  • Any known metal implants or allergy to contrast agents
  • Pregnancy (as part of standard of care, all female participants will be administered a urine pregnancy test prior to surgery. A negative result is required to proceed with surgery per SOC and thus, participate in the study) and those planning to become pregnant during the duration of the study
  • Any condition with known bleeding disorders, thrombus formation risk factors, or overlying wound and skin infections
  • Any condition in the opinion of the primary investigator that would compromise the integrity of the data collection or outcomes being assessed
  • Any other medical condition that in the opinion of the primary investigator would constitute a relative contraindication to study participation (e.g., Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, SLE, scleroderma, polymyositis, Ehlers-Danlos syndrome, osteoporosis)

Treatment and study plan

Autologous Mesenchymal Stromal Cells

Biological

Autologous mesenchymal stromal/stem cells extracted from the subject during a routine standard of care ACL reconstruction surgery and reintroduced in one clinic visit approximately 21 days after completion of the surgery. After being removed from the patient, the cells will be cultured, modified, and harvested to become the final investigational product. Each subject will receive 1.5 ml of the investigative drug. This will contain 5x10^7 (50 million) autologous MSCs.

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: 4-5 weeks postop, 6-7 weeks postop, 3.5 months postop, 6 months postop

    Participants will be asked via a follow-up phone call following injection whether or not they have experienced any adverse events following the injection. They will be assessed at all remaining standard of care follow up visits and staff will inquire about adverse events.

  2. Knee Function

    Time frame: Preoperative appointment, 6 weeks postop, 3.5 months postop, 6 months postop

    Knee function will be assessed through patient reported responses on the Knee Injury and Osteoarthritis Outcome Score (KOOS) survey via REDCap. The Questionnaire has five subscales which are separately scored (pain, function in daily living, function in sport and recreation, other symptoms and knee-related quality of life). Final score will be determined on a scale of 0-100 where 100 indicates no symptoms and 0 indicates extreme symptoms.

  3. Knee Function

    Time frame: Preoperative appointment, 6 weeks postop, 3.5 months postop, 6 months postop

    Function will be assessed with the International Knee Documentation Committee Subjective Knee Form (IKDC) which contains sections on knee symptoms, function, and sports activities. Total score will range from 0 (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

  4. Knee Function

    Time frame: Preoperative appointment, 6 weeks postop, 3.5 months postop, 6 months postop

    Active and passive Range of Motion (ROM) of the operated and contralateral knee will be documented by the physician. This will be determined by the measurement of angles in each plane at the body's joints.

Secondary outcomes

  1. Knee Pain

    Time frame: Preoperative appointment, 6 weeks postop, 3.5 months postop, 6 months postop

    Pain levels will be assessed using patient reported outcomes via REDCap. The Visual Analogue Scale will ask participants to mark on a line, using a ruler, how much pain they are in. The score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.

  2. Return to Sport Time

    Time frame: 3 months postop

    Return to sport time will be evaluated via the subject's standard of care (SOC) physical therapy notes in their chart.

  3. Knee Swelling

    Time frame: Preoperative appointment, 6 weeks postop, 3.5 months postop, 6 months postop

    The trans-patellar circumference of both knees will be measured at the standard of care (SOC) appointments the subject will attend throughout the study to monitor swelling. Knees will be measured utilizing a flexible measuring tape and the affected knee will be compared to the unaffected knee to verify the difference in size, and therefore the severity of swelling. The greater the difference in size between knees, the more severe the swelling.

  4. Knee Pain

    Time frame: Preoperative appointment, 6 weeks postop, 3.5 months postop, 6 months postop

    Questions related to pain will also be assessed on the International Knee Documentation Committee Subjective Knee Form (IKDC), although this is not its primary focus. Total score will range from 0 (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

Study contacts

Contact information is provided by the study sponsor or research team.

Haley Goble

CONTACT

[email protected]

713-441-3930

Madison Bowden

CONTACT

[email protected]

713-363-7390

Sponsors and collaborators

Lead sponsor

The Methodist Hospital Research Institute

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Jan 29, 2025
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.